SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+5.7%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.45B
AUM Growth
+$2.45B
(+3.4%)
Cap. Flow
+$258M
Cap. Flow
% of AUM
10.51%
Top 10 Holdings %
Top 10 Hldgs %
45.17%
Holding
110
New
9
Increased
24
Reduced
21
Closed
11
Top Buys
| 1 |
UnitedHealth
UNH
|
$74.5M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$41.6M |
| 3 |
Biohaven
BHVN
|
$41.5M |
| 4 |
Apple
AAPL
|
$39.3M |
| 5 |
Sysco
SYY
|
$37.2M |
Top Sells
| 1 |
argenx
ARGX
|
$48M |
| 2 |
Cigna
CI
|
$43.7M |
| 3 |
McKesson
MCK
|
$32M |
| 4 |
Verizon
VZ
|
$23.5M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$22.8M |
Sector Composition
| 1 | Healthcare | 65.51% |
| 2 | Technology | 11.21% |
| 3 | Communication Services | 6.91% |
| 4 | Consumer Discretionary | 6.1% |
| 5 | Financials | 3.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biohaven
BHVN
$1.63B
| $180M | 6.63% | 5,199,219 +1,196,173 | +30% | +$41.5M |
|
2
Insmed
INSM
$28.8B
| $169M | 6.21% | 2,521,800 +498,800 | +25% | +$33.4M |
|
3
Kura Oncology
KURA
$686M
| $146M | 5.35% | 7,069,627 | – | – |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $107M | 3.94% | 1,565,996 +606,798 | +63% | +$41.6M |
|
5
Arcutis Biotherapeutics
ARQT
$1.86B
| $93M | 3.42% | 10,004,492 +2,127,195 | +27% | +$19.8M |
|
6
Ultragenyx Pharmaceutical
RARE
$2.89B
| $84.7M | 3.11% | 2,061,426 +384,615 | +23% | +$15.8M |
|
7
Meta Platforms (Facebook)
META
$1.86T
| $84.3M | 3.1% | 167,169 -6,436 | -4% | -$3.25M |
|
8
Arcellx
ACLX
$3.85B
| $83.7M | 3.07% | 1,516,254 -46,100 | -3% | -$2.54M |
|
|
9
UnitedHealth
UNH
$281B
| $82.2M | 3.02% | 161,468 +146,345 | +968% | +$74.5M |
|
|
10
Apple
AAPL
$3.45T
| $76.5M | 2.81% | 363,357 +186,677 | +106% | +$39.3M |
|
11
Amazon
AMZN
$2.44T
| $68.8M | 2.53% | 356,268 -694 | -0.2% | -$134K |
|
12
89bio
ETNB
$1.34B
| $64.3M | 2.36% | 8,031,845 +1,733,841 | +28% | +$13.9M |
|
13
TSMC
TSM
$1.2T
| $61M | 2.24% | 350,752 +21,400 | +6% | +$3.72M |
|
14
Advanced Micro Devices
AMD
$264B
| $56.1M | 2.06% | 345,998 +4,299 | +1% | +$697K |
|
15
Elevance Health
ELV
$71.8B
| $49.5M | 1.82% | 91,442 +40,517 | +80% | +$22M |
|
16
KalVista Pharmaceuticals
KALV
$678M
| $49.4M | 1.81% | 4,192,005 | – | – |
|
17
Royalty Pharma
RPRX
$15.6B
| $49.2M | 1.81% | 1,866,361 -384,000 | -17% | -$10.1M |
|
18
Microsoft
MSFT
$3.77T
| $46.5M | 1.71% | 104,033 +24,716 | +31% | +$11M |
|
19
EyePoint Pharmaceuticals
EYPT
$797M
| $45M | 1.65% | 5,175,823 +1,411,935 | +38% | +$12.3M |
|
20
Apollo Global Management
APO
$77.9B
| $41.9M | 1.54% | 354,486 -16,150 | -4% | -$1.91M |
|
21
AT&T
T
$209B
| $41.8M | 1.54% | 2,186,886 -211,733 | -9% | -$4.05M |
|
|
22
Sysco
SYY
$38.5B
| $37.2M | 1.37% | +520,900 | New | +$37.2M |
|
|
CTNM
23
Contineum Therapeutics
CTNM
$293M
| $36.2M | 1.33% | +2,053,334 | New | +$36.2M |
|
24
Coca-Cola
KO
$297B
| $35.7M | 1.31% | 560,613 +14,113 | +3% | +$898K |
|
25
Goldman Sachs
GS
$226B
| $35.3M | 1.3% | 77,948 -31,942 | -29% | -$14.4M |
|